Akeso (09926) is up over 5%. As of press time, it is up 4.45% and traded at HKD 42.25, with a turnover of 0.132 billion HKD.
According to the WiseNews app, Akeso (09926) is up over 5%. As of press time, it is up 4.45% and traded at HKD 42.25, with a turnover of 0.132 billion HKD.
In terms of news, Akeso announced that the market application for its self-developed and globally pioneering dual-specific antibody Idivab (iwosci, PD-1/VEGF) monotherapy for first-line treatment of locally advanced or metastatic non-small cell lung cancer with PD-L1 expression has been officially accepted by the China National Medical Products Administration. At present, iwosci has been approved for one indication in mainland China, and five Phase III clinical trials are ongoing.
Tube Securities previously pointed out that AK112 would be approved for marketing in May 2024, for the treatment of locally advanced or metastatic nsqNSCLC progressing after EGFR-TKI, with a total review time of less than 10 months, which exceeded expectations. Coupled with the data readout from the head-to-head comparison with K drugs, the commercial prospects of AK112 and the certainty of overseas success have been greatly improved. The bank has raised its domestic peak sales forecast by CNY 6 billion and its overseas peak sales forecast by USD 3 billion. The bank believes that the company has the potential to evolve into a first-class biopharmaceutical company in China with international competitiveness and is currently undervalued in terms of market cap.